URGN
UroGen Pharma Ltd
NASDAQ: URGN · HEALTHCARE · BIOTECHNOLOGY
$23.83
+2.10% today
Updated 2026-04-30
Market cap
$1.14B
P/E ratio
—
P/S ratio
10.35x
EPS (TTM)
$-3.19
Dividend yield
—
52W range
$3 – $30
Volume
0.8M
UroGen Pharma Ltd (URGN) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.23M | $4.36M | $19.39M | $23.06M | $75.55M | $103.56M | $202.39M | $122.00M | $119.75M | $135.62M | $178.31M | $285.71M |
| Cash & equivalents | $3.04M | $3.87M | $17.98M | $21.36M | $37.00M | $101.32M | $49.69M | $52.86M | $44.36M | $55.41M | $95.00M | $171.99M |
| Current assets | $3.15M | $4.29M | $19.13M | $22.04M | $74.47M | $102.24M | $148.63M | $115.62M | $114.39M | $128.91M | $169.19M | $276.13M |
| Total liabilities | $484000.00 | $891000.00 | $2.24M | $6.75M | $7.04M | $13.46M | $22.09M | $25.65M | $111.33M | $224.98M | $243.52M | $294.51M |
| Current liabilities | $484000.00 | $891000.00 | $2.24M | $3.14M | $7.04M | $13.46M | $19.48M | $21.44M | $22.38M | $23.92M | $31.21M | $45.95M |
| Long-term debt | — | — | $872000.00 | $3.61M | — | — | — | — | — | $97.54M | $98.55M | $121.73M |
| Shareholder equity | $2.74M | $3.47M | $17.15M | $16.31M | $68.52M | $90.09M | $180.30M | $96.36M | $8.41M | $-89.36M | $-65.21M | $-8.80M |
| Retained earnings | $-8.11M | $-12.58M | $-25.27M | $-27.21M | $-47.21M | $-122.87M | $-228.02M | $-356.50M | $-467.32M | $-577.10M | $-679.35M | $-806.22M |
| Accounts receivable | — | — | — | $83000.00 | $198000.00 | — | — | $7.05M | $11.72M | $12.70M | $15.44M | $20.30M |
| Inventory | — | — | — | $105000.00 | $316000.00 | — | — | $1.96M | $4.83M | $4.33M | $5.67M | $9.23M |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — |